Retroviral Replicating Vectors Mediated Prodrug Activator Gene Therapy in a Gastric Cancer Model
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241914823 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Hiroaki Fujino und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular and Genetic Therapeutics, Institute of Advanced Medical Science, Hyogo Medical University, Hyogo 663-8501, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Prodrugs. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grant-in-Aid for Scientific Research B from the Ministry of Education, Culture, Sports, Science and Technology (MEXT).
Abstract (Originalsprache)
Retroviral replicating vectors (RRVs) selectively replicate and can specifically introduce prodrug-activating genes into tumor cells, whereby subsequent prodrug administration induces the death of the infected tumor cells. We assessed the ability of two distinct RRVs generated from amphotropic murine leukemia virus (AMLV) and gibbon ape leukemia virus (GALV), which infect cells via type-III sodium-dependent phosphate transporters, PiT-2 and PiT-1, respectively, to infect human gastric cancer (GC) cells. A quantitative RT-PCR showed that all tested GC cell lines had higher expression levels of PiT-2 than PiT-1. Accordingly, AMLV, encoding a green fluorescent protein gene, infected and replicated more efficiently than GALV in most GC cell lines, whereas both RRVs had a low infection rate in human fibroblasts. RRV encoding a cytosine deaminase prodrug activator gene, which converts the prodrug 5-flucytosine (5-FC) to the active drug 5-fluorouracil, showed that AMLV promoted superior 5-FC-induced cytotoxicity compared with GALV, which correlated with the viral receptor expression level and viral spread. In MKN-74 subcutaneous xenograft models, AMLV had significant antitumor effects compared with GALV. Furthermore, in the MKN-74 recurrent tumor model in which 5-FC was discontinued, the resumption of 5-FC administration reduced the tumor volume. Thus, RRV-mediated prodrug activator gene therapy might be beneficial for treating human GC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular and Genetic Therapeutics, Institute of Advanced Medical Science, Hyogo Medical University, Hyogo 663-8501, Japan.
- Departments of Biomedical Chemistry, School of Science and Technology, Kwansei Gakuin University, Hyogo 669-1330, Japan.
- Laboratory of Functional Molecular Chemistry, Kobe Pharmaceutical University, Hyogo 658-8558, Japan.
- Departments of Neurological Surgery and Radiation Oncology, University of California, San Francisco, CA 94143, USA.
ORCID-Profile: Toru Takarada, Noriyuki Kasahara, Shuji Kubo
Förderung
- Grant-in-Aid for Scientific Research B from the Ministry of Education, Culture, Sports, Science and Technology (MEXT)
Zitieren
APA
Fujino, H., Sonoda-Fukuda, E., Isoda, L., Kawabe, A., Takarada, T., Kasahara, N., & Kubo, S. (2023). Retroviral Replicating Vectors Mediated Prodrug Activator Gene Therapy in a Gastric Cancer Model. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241914823
Vancouver
Fujino H, Sonoda-Fukuda E, Isoda L, Kawabe A, Takarada T, Kasahara N, et al. Retroviral Replicating Vectors Mediated Prodrug Activator Gene Therapy in a Gastric Cancer Model. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241914823
BibTeX
@article{Fujino2023,
author = {Fujino, Hiroaki and Sonoda-Fukuda, Emiko and Isoda, Lisa and Kawabe, Ayane and Takarada, Toru and Kasahara, Noriyuki and Kubo, Shuji},
title = {Retroviral Replicating Vectors Mediated Prodrug Activator Gene Therapy in a Gastric Cancer Model},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241914823}
}
EUVIMED